Invasive lobular breast cancer and its variants: How special are they for systemic therapy decisions?

Critical Reviews in Oncology/Hematology

Volumn 92, Issue 3, 2014, Pages 235-257

  Guiu, Séverine ^a,b   Wolfer, Anita ^b   Jacot, William ^c   Fumoleau, Pierre ^a   Romieu, Gilles ^c   Bonnetain, Franck ^d   Fiche, Maryse ^e  

^a Georges Francois Leclerc Cancer Center   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c Institute of Neuroscience of Montpellier   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

^e UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

Author keywords

Invasive breast cancer; Invasive lobular carcinoma; Luminal breast cancer; Pleomorphic invasive lobular carcinoma; Predictive factor; Prognosis; Tubulo lobular carcinoma

Indexed keywords

LETROZOLE; TAMOXIFEN; TRASTUZUMAB; UVOMORULIN;

BREAST CARCINOMA; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CLINICAL EFFECTIVENESS; COMPARATIVE GENOMIC HYBRIDIZATION; DIAGNOSTIC EQUIPMENT; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL DECISION MAKING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SYSTEMIC THERAPY; TREATMENT OUTCOME; BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; GENETIC SCREENING; GENOMICS; MORTALITY; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

BREAST NEOPLASMS; CARCINOMA, LOBULAR; FEMALE; GENETIC TESTING; GENOMICS; HUMANS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84912571097     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.07.003     Document Type: Review

References (185)

1. Lakhani S.R., Schnitt E.I., Hoon Tan S.J., Van de Vijver P.M. WHO classification of tumors of the breast 2012, IARC, Lyon. 4th ed.
2. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
3. Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thurlimann B., et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013, 24(9):2206-2223.
4. Wellings S.R., Jensen H.M., Marcum R.G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Nat Cancer Inst 1975, 55(2):231-273.
5. Li C.I., Weiss N.S., Stanford J.L., Daling J.R. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000, 88(11):2570-2577.
6. Talman Moller M., Jensen M., Rank F. Invasive lobular breast cancer, prognostic significance of histological malignancy grading. Acta Oncol 2007, 46(6):803-809.
7. Biglia N., Mariani L., Sgro L., Mininanni P., Moggio G., Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer 2007, 14(3):549-567.
8. Suhrke P., Maehlen J., Zahl P.H. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway. Breast J 2012, 18(6):549-556.
9. Altekruse S.F., Krapcho K.C.M. SEER cancer statistic review NCI 1975-2007 2010, National Cancer Institute, Bethesda, Md.
10. Simpson P.T., Reis-Filho J.S., Gale T., Lakhani S.R. Molecular evolution of breast cancer. J Pathol 2005, 205(2):248-254.
11. Abdel-Fatah T.M., Powe D.G., Hodi Z., Lee A.H., Reis-Filho J.S., Ellis I.O. High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007, 31(3):417-426.
12. Abdel-Fatah T.M., Powe D.G., Hodi Z., Reis-Filho J.S., Lee A.H., Ellis I.O. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008, 32(4):513-523.
13. Tavassoli F., Eusebi V. Tumors of the mammary gland. AFIP Atlas of tumor pathology, Fascicle 10 Tumors of the mammary gland, May 2009.
14. Rakha E.A., Ellis I.O. Lobular breast carcinoma and its variants. Semin Diagn Pathol 2010, 27(1):49-61.
15. Ferlicot S., Vincent-Salomon A., Medioni J., Genin P., Rosty C., Sigal-Zafrani B., et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004, 40(3):336-341.
16. Lamovec J., Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol 1991, 48(1):28-33.
17. Arpino G., Bardou V.J., Clark G.M., Elledge R.M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004, 6(3):R149-R156.
18. du Toit R.S., Locker A.P., Ellis I.O., Elston C.W., Nicholson R.I., Robertson J.F., et al. An evaluation of differences in prognosis, recurrence patterns and receptor status between invasive lobular and other invasive carcinomas of the breast. Eur J Surg Oncol 1991, 17(3):251-257. (the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
19. Martinez V., Azzopardi J.G. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology 1979, 3(6):467-488.
20. Fisher E.R., Gregorio R.M., Redmond C., Fisher B. Tubulolobular invasive breast cancer: a variant of lobular invasive cancer. Hum Pathol 1977, 8(6):679-683.
21. Dixon J.M., Anderson T.J., Page D.L., Lee D., Duffy S.W. Infiltrating lobular carcinoma of the breast. Histopathology 1982, 6(2):149-161.
22. Tot T. The diffuse type of invasive lobular carcinoma of the breast: morphology and prognosis. Virchows Archiv 2003, 443(6):718-724. (an international journal of pathology).
23. Cocquyt V.F., Blondeel P.N., Depypere H.T., Praet M.M., Schelfhout V.R., Silva O.E., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003, 29(4):361-367. (the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
24. Cristofanilli M., Gonzalez-Angulo A., Sneige N., Kau S.W., Broglio K., Theriault R.L., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23(1):41-48.
25. Delpech Y., Coutant C., Hsu L., Barranger E., Iwamoto T., Barcenas C.H., et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 2013, 108(2):285-291.
26. Prat A., Ellis M.J., Perou C.M. Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012, 9(1):48-57.
27. Weigelt B., Geyer F.C., Natrajan R., Lopez-Garcia M.A., Ahmad A.S., Savage K., et al. The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010, 220(1):45-57.
28. Foote F.W., Stewart F.W. A histologic classification of carcinoma of the breast. Surgery 1946, 19:74-99.
29. Rakha E.A., El-Sayed M.E., Menon S., Green A.R., Lee A.H., Ellis I.O. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast. Breast Cancer Res Treat 2008, 111(1):121-127.
30. Iorfida M., Maiorano E., Orvieto E., Maisonneuve P., Bottiglieri L., Rotmensz N., et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 2012, 133(2):713-723.
31. DiCostanzo D., Rosen P.P., Gareen I., Franklin S., Lesser M. Prognosis in infiltrating lobular carcinoma. An analysis of classical and variant tumors. Am J Surg Pathol 1990, 14(1):12-23.
32. du Toit R.S., Locker A.P., Ellis I.O., Elston C.W., Nicholson R.I., Blamey R.W. Invasive lobular carcinomas of the breast-the prognosis of histopathological subtypes. Br J Cancer 1989, 60(4):605-609.
33. Buchanan C.L., Flynn L.W., Murray M.P., Darvishian F., Cranor M.L., Fey J.V., et al. Is pleomorphic lobular carcinoma really a distinct clinical entity?. J Surg Oncol 2008, 98(5):314-317.
34. Eusebi V., Magalhaes F., Azzopardi J.G. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum Pathol 1992, 23(6):655-662.
35. Green I., McCormick B., Cranor M., Rosen P.P. A comparative study of pure tubular and tubulolobular carcinoma of the breast. Am J Surg Pathol 1997, 21(6):653-657.
36. Esposito N.N., Chivukula M., Dabbs D.J. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol 2007, 20(1):130-138. (an official journal of the United States and Canadian Academy of Pathology, Inc.).
37. Sinha P.S., Bendall S., Bates T. Does routine grading of invasive lobular cancer of the breast have the same prognostic significance as for ductal cancers?. Eur J Surg Oncol 2000, 26(8):733-737. (the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
38. Mokbel K. Grading of infiltrating lobular carcinoma. Eur J Surg Oncol 2001, 27(6):609-610. (the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
39. Sastre-Garau X., Jouve M., Asselain B., Vincent-Salomon A., Beuzeboc P., Dorval T., et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996, 77(1):113-120.
40. Bane A.L., Tjan S., Parkes R.K., Andrulis I., O'Malley F.P. Invasive lobular carcinoma: to grade or not to grade. Mod Pathol 2005, 18(5):621-628. (an official journal of the United States and Canadian Academy of Pathology, Inc.).
41. Mathieu M.C., Rouzier R., Llombart-Cussac A., Sideris L., Koscielny S., Travagli J.P., et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004, 40(3):342-351.
42. Toikkanen S., Pylkkanen L., Joensuu H. Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997, 76(9):1234-1240.
43. Rakha E.A., van Deurzen C.H., Paish E.C., Macmillan R.D., Ellis I.O., Lee A.H. Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. Mod Pathol 2013, 26(4):496-501. (an official journal of the United States and Canadian Academy of Pathology, Inc.).
44. Berx G., Cleton-Jansen A.M., Strumane K., de Leeuw W.J., Nollet F., van Roy F., et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996, 13(9):1919-1925.
45. Rakha E.A., Abd El Rehim D., Pinder S.E., Lewis S.A., Ellis I.O. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology 2005, 46(6):685-693.
46. Rakha E.A., Patel A., Powe D.G., Benhasouna A., Green A.R., Lambros M.B., et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010, 34(10):1472-1479.
47. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
48. Wheeler D.T., Tai L.H., Bratthauer G.L., Waldner D.L., Tavassoli F.A. Tubulolobular carcinoma of the breast: an analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol 2004, 28(12):1587-1593.
49. De Leeuw W.J., Berx G., Vos C.B., Peterse J.L., Van de Vijver M.J., Litvinov S., et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997, 183(4):404-411.
50. Simpson P.T., Reis-Filho J.S., Lambros M.B., Jones C., Steele D., Mackay A., et al. Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 2008, 215(3):231-244.
51. Kuroda H., Tamaru J., Takeuchi I., Ohnisi K., Sakamoto G., Adachi A., et al. Expression of E-cadherin, alpha-catenin, and beta-catenin in tubulolobular carcinoma of the breast. Virchows Archiv 2006, 448(4):500-505. (an international journal of pathology).
52. Rakha E.A., El-Sayed M.E., Powe D.G., Green A.R., Habashy H., Grainge M.J., et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008, 44(1):73-83.
53. Sikora M.J., Jankowitz R.C., Dabbs D.J., Oesterreich S. Invasive lobular carcinoma of the breast: patient response to systemic endocrine therapy and hormone response in model systems. Steroids 2013, 78(6):568-575.
54. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013, 24(3):661-668.
55. Radhi J.M. Immunohistochemical analysis of pleomorphic lobular carcinoma: higher expression of p53 and chromogranin and lower expression of ER and PgR. Histopathology 2000, 36(2):156-160.
56. Colleoni M., Rotmensz N., Maisonneuve P., Mastropasqua M.G., Luini A., Veronesi P., et al. Outcome of special types of luminal breast cancer. Ann Oncol 2012, 23(6):1428-1436.
57. Yu J., Dabbs D.J., Shuai Y., Niemeier L.A., Bhargava R. Classical-type invasive lobular carcinoma with HER2 overexpression: clinical, histologic, and hormone receptor characteristics. Am J Clin Pathol 2011, 136(1):88-97.
58. Hoff E.R., Tubbs R.R., Myles J.L., Procop G.W. HER2/neu amplification in breast cancer: stratification by tumor type and grade. Am J Clin Pathol 2002, 117(6):916-921.
59. Varga Z., Zhao J., Ohlschlegel C., Odermatt B., Heitz P.U. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. Histopathology 2004, 44(4):332-338.
60. Frolik D., Caduff R., Varga Z. Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology 2001, 39(5):503-513.
61. Metzger-Filho O., Procter M., de Azambuja E., Leyland-Jones B., Gelber R.D., Dowsett M., et al. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J Clin Oncol 2013, 31(16):1954-1960.
62. Riva C., Dainese E., Caprara G., Rocca P.C., Massarelli G., Tot T., et al. Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Archiv 2005, 447(4):695-700. (an international journal of pathology).
63. Flagiello D., Gerbault-Seureau M., Sastre-Garau X., Padoy E., Vielh P., Dutrillaux B. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 1998, 23(4):300-306.
64. Loveday R.L., Greenman J., Simcox D.L., Speirs V., Drew P.J., Monson J.R., et al. Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer 2000, 86(4):494-500.
65. Gunther K., Merkelbach-Bruse S., Amo-Takyi B.K., Handt S., Schroder W., Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001, 193(1):40-47.
66. Loo L.W., Grove D.I., Williams E.M., Neal C.L., Cousens L.A., Schubert E.L., et al. Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. Cancer Res 2004, 64(23):8541-8549.
67. Bertucci F., Orsetti B., Negre V., Finetti P., Rouge C., Ahomadegbe J.C., et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008, 27(40):5359-5372.
68. Stange D.E., Radlwimmer B., Schubert F., Traub F., Pich A., Toedt G., et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res 2006, 12(2):345-352.
69. Gruel N., Lucchesi C., Raynal V., Rodrigues M.J., Pierron G., Goudefroye R., et al. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010, 46(13):2399-2407.
70. Korkola J.E., DeVries S., Fridlyand J., Hwang E.S., Estep A.L., Chen Y.Y., et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003, 63(21):7167-7175.
71. Zhao H., Langerod A., Ji Y., Nowels K.W., Nesland J.M., Tibshirani R., et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004, 15(6):2523-2536.
72. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Nat Acad Sci USA 2001, 98(19):10869-10874.
73. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Nat Acad Sci USA 2003, 100(14):8418-8423.
74. Hu Z., Fan C., Oh D.S., Marron J.S., He X., Qaqish B.F., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
75. Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., Viens P., et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123(1):236-240.
76. Bertucci F., Finetti P., Rougemont J., Charafe-Jauffret E., Cervera N., Tarpin C., et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005, 65(6):2170-2178.
77. Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol 2011, 29(17):2342-2349.
78. Guedj M., Marisa L., de Reynies A., Orsetti B., Schiappa R., Bibeau F., et al. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31(9):1196-1206.
79. Kreike B., Halfwerk H., Armstrong N., Bult P., Foekens J.A., Veltkamp S.C., et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009, 15(12):4181-4190.
80. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65.
81. Lips E.H., Mulder L., de Ronde J.J., Mandjes I.A., Vincent A., Vrancken Peeters M.T., et al. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat 2012, 131(3):827-836.
82. Nielsen T.O., Parker J.S., Leung S., Voduc D., Ebbert M., Vickery T., et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16(21):5222-5232.
83. Perreard L., Fan C., Quackenbush J.F., Mullins M., Gauthier N.P., Nelson E., et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006, 8(2):R23.
84. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-5685.
85. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
86. Cheang M.C., Chia S.K., Voduc D., Gao D., Leung S., Snider J., et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Nat Cancer Inst 2009, 101(10):736-750.
87. Hugh J., Hanson J., Cheang M.C., Nielsen T.O., Perou C.M., Dumontet C., et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009, 27(8):1168-1176.
88. Park S., Koo J.S., Kim M.S., Park H.S., Lee J.S., Kim S.I., et al. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast 2012, 21(1):50-57.
89. Cancello G., Maisonneuve P., Rotmensz N., Viale G., Mastropasqua M.G., Pruneri G., et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 2011, 127(3):713-720.
90. Skarlos P., Christodoulou C., Kalogeras K.T., Eleftheraki A.G., Bobos M., Batistatou A., et al. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 2012, 69(2):533-546.
91. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360(8):790-800.
92. Badve S.S., Baehner F.L., Gray R.P., Childs B.H., Maddala T., Liu M.L., et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol 2008, 26(15):2473-2481.
93. Cobleigh M.A., Tabesh B., Bitterman P., Baker J., Cronin M., Liu M.L., et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005, 11(24 Pt 1):8623-8631.
94. Joh J.E., Esposito N.N., Kiluk J.V., Laronga C., Lee M.C., Loftus L., et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 2011, 16(11):1520-1526.
95. Kelly C.M., Krishnamurthy S., Bianchini G., Litton J.K., Gonzalez-Angulo A.M., Hortobagyi G.N., et al. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer 2010, 116(22):5161-5167.
96. Wolf I., Ben-Baruch N., Shapira-Frommer R., Rizel S., Goldberg H., Yaal-Hahoshen N., et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer 2008, 112(4):731-736.
97. Allison K.H., Kandalaft P.L., Sitlani C.M., Dintzis S.M., Gown A.M. Routine pathologic parameters can predict Oncotype DX recurrence scores in subsets of ER positive patients: who does not always need testing?. Breast Cancer Res Treat 2012, 131(2):413-424.
98. Kok M., Koornstra R.H., Mook S., Hauptmann M., Fles R., Jansen M.P., et al. Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer. Breast 2012, 21(6):769-778.
99. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van't Veer L.J., van Dam F.S., Karsenberg K., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007, 8(12):1079-1087.
100. Hartmann S., Gerber B., Elling D., Heintze K., Reimer T. The 70-gene signature as prognostic factor for elderly women with hormone receptor-positive, HER2-negative breast cancer. Breast Care (Basel) 2012, 7(1):19-24.
101. Mook S., Knauer M., Bueno-de-Mesquita J.M., Retel V.P., Wesseling J., Linn S.C., et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010, 17(5):1406-1413.
102. Mook S., Schmidt M.K., Weigelt B., Kreike B., Eekhout I., van de Vijver M.J., et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010, 21(4):717-722.
103. Mook S., Schmidt M.K., Viale G., Pruneri G., Eekhout I., Floore A., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116(2):295-302.
104. ®)) among breast cancer patients with 4-9 positive lymph nodes. Breast 2013, 22(5):682-690.
105. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver M.J., Rutgers E.J., et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119(3):551-558.
106. Knauer M., Cardoso F., Wesseling J., Bedard P.L., Linn S.C., Rutgers E.J., et al. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010, 103(12):1788-1793.
107. Sotiriou C., Wirapati P., Loi S., Harris A., Fox S., Smeds J., et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Nat Cancer Inst 2006, 98(4):262-272.
108. Bertucci F., Finetti P., Roche H., Le Doussal J.M., Marisa L., Martin A.L., et al. Comparison of the prognostic value of genomic grade index, Ki67 expression and mitotic activity index in early node-positive breast cancer patients. Ann Oncol 2013, 24(3):625-632.
109. Reyal F., Bollet M.A., Caly M., Gentien D., Carpentier S., Peyro-Saint-Paul H., et al. Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLoS One 2012, 7(4):e35184.
110. Metzger-Filho O., Michiels S., Bertucci F., Catteau A., Salgado R., Galant C., et al. Genomic grade adds prognostic value in invasive lobular carcinoma. Ann Oncol 2013, 24(2):377-384.
111. Parker J.S., Mullins M., Cheang M.C., Leung S., Voduc D., Vickery T., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27(8):1160-1167.
112. Ma X.J., Salunga R., Dahiya S., Wang W., Carney E., Durbecq V., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14(9):2601-2608.
113. Filipits M., Rudas M., Jakesz R., Dubsky P., Fitzal F., Singer C.F., et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011, 17(18):6012-6020.
114. Buttitta F., Felicioni L., Barassi F., Martella C., Paolizzi D., Fresu G., et al. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J Pathol 2006, 208(3):350-355.
115. Barbareschi M., Buttitta F., Felicioni L., Cotrupi S., Barassi F., Del Grammastro M., et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007, 13(20):6064-6069.
116. Kalinsky K., Jacks L.M., Heguy A., Patil S., Drobnjak M., Bhanot U.K., et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009, 15(16):5049-5059.
117. Christgen M., Noskowicz M., Schipper E., Christgen H., Heil C., Krech T., et al. Oncogenic PIK3CA mutations in lobular breast cancer progression. Genes Chromosomes Cancer 2013, 52(1):69-80.
118. Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery 2013, 3(2):224-237.
119. Li C.I., Moe R.E., Daling J.R. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003, 163(18):2149-2153.
120. Louwman M.W., Vriezen M., van Beek M.W., Nolthenius-Puylaert M.C., van der Sangen M.J., Roumen R.M., et al. Uncommon breast tumors in perspective: incidence, treatment and survival in The Netherlands. Int J Cancer 2007, 121(1):127-135.
121. Dian D., Herold H., Mylonas I., Scholz C., Janni W., Sommer H., et al. Survival analysis between patients with invasive ductal and invasive lobular breast cancer. Arch Gynecol Obstet 2009, 279(1):23-28.
122. Bharat A., Gao F., Margenthaler J.A. Tumor characteristics and patient outcomes are similar between invasive lobular and mixed invasive ductal/lobular breast cancers but differ from pure invasive ductal breast cancers. Am J Surg 2009, 198(4):516-519.
123. Silverstein M.J., Lewinsky B.S., Waisman J.R., Gierson E.D., Colburn W.J., Senofsky G.M., et al. Infiltrating lobular carcinoma, Is it different from infiltrating duct carcinoma?. Cancer 1994, 73(6):1673-1677.
124. Wasif N., Maggard M.A., Ko C.Y., Giuliano A.E. Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010, 17(7):1862-1869.
125. Weiss M.C., Fowble B.L., Solin L.J., Yeh I.T., Schultz D.J. Outcome of conservative therapy for invasive breast cancer by histologic subtype. Int J Radiat Oncol Biol Phys 1992, 23(5):941-947.
126. Chung M.A., Cole B., Wanebo H.J., Bland K.I., Chang H.R. Optimal surgical treatment of invasive lobular carcinoma of the breast. Ann Surg Oncol 1997, 4(7):545-550.
127. Rosen P.P., Groshen S., Kinne D.W. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991, 9(9):1650-1661.
128. Peiro G., Bornstein B.A., Connolly J.L., Gelman R., Hetelekidis S., Nixon A.J., et al. The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat 2000, 59(1):49-54.
129. Winchester D.J., Chang H.R., Graves T.A., Menck H.R., Bland K.I., Winchester D.P. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998, 186(4):416-422.
130. Mersin H., Yildirim E., Gulben K., Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma?. Eur J Surg Oncol 2003, 29(4):390-395. (the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology).
131. Lee J.H., Park S., Park H.S., Park B.W. Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J Surg Oncol 2010, 8:34.
132. Santiago R.J., Harris E.E., Qin L., Hwang W.T., Solin L.J. Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: the University of Pennsylvania experience. Cancer 2005, 103(12):2447-2454.
133. Vo T.N., Meric-Bernstam F., Yi M., Buchholz T.A., Ames F.C., Kuerer H.M., et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006, 192(4):552-555.
134. Moran M.S., Yang Q., Haffty B.G. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J 2009, 15(6):571-578.
135. Fritz P., Klenk S., Goletz S., Gerteis A., Simon W., Brinkmann F., et al. Clinical impacts of histological subtyping primary breast cancer. Anticancer Res 2010, 30(12):5137-5144.
136. Fortunato L., Mascaro A., Poccia I., Andrich R., Amini M., Costarelli L., et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol 2012, 19(4):1107-1114.
137. Kwast A.B., Groothuis-Oudshoorn K.C., Grandjean I., Ho V.K., Voogd A.C., Menke-Pluymers M.B., et al. Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Res Treat 2012, 135(1):271-280.
138. Jayasinghe U.W., Bilous A.M., Boyages J. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?. Breast J 2007, 13(5):479-485.
139. Cao A.Y., Huang L., Wu J., Lu J.S., Liu G.Y., Shen Z.Z., et al. Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J Surg Oncol 2012, 10:152.
140. Bonnefoi H., Piccart M., Bogaerts J., Mauriac L., Fumoleau P., Brain E., et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011, 12(6):527-539.
141. Fernandez B., Paish E.C., Green A.R., Lee A.H., Macmillan R.D., Ellis I.O., et al. Lymph-node metastases in invasive lobular carcinoma are different from those in ductal carcinoma of the breast. J Clin Pathol 2011, 64(11):995-1000.
142. Fondrinier E., Guerin O., Lorimier G. A comparative study of metastatic patterns of ductal and lobular carcinoma of the breast from two matched series (376 patients). Bull Cancer 1997, 84(12):1101-1107.
143. Korhonen T., Huhtala H., Holli K. A comparison of the biological and clinical features of invasive lobular and ductal carcinomas of the breast. Breast Cancer Res Treat 2004, 85(1):23-29.
144. Mhuircheartaigh N., Curran C., Hennessy E., Kerin M.J. Prospective matched-pair comparison of outcome after treatment for lobular and ductal breast carcinoma. Br J Surg 2008, 95(7):827-833.
145. Viale G., Rotmensz N., Maisonneuve P., Orvieto E., Maiorano E., Galimberti V., et al. Lack of prognostic significance of classic lobular breast carcinoma: a matched, single institution series. Breast Cancer Res Treat 2009, 117(1):211-214.
146. Pestalozzi B.C., Zahrieh D., Mallon E., Gusterson B.A., Price K.N., Gelber R.D., et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008, 26(18):3006-3014.
147. Weidner N., Semple J.P. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum Pathol 1992, 23(10):1167-1171.
148. Bentz J.S., Yassa N., Clayton F. Pleomorphic lobular carcinoma of the breast: clinicopathologic features of 12 cases. Mod Pathol 1998, 11(9):814-822. (an official journal of the United States and Canadian Academy of Pathology, Inc.).
149. Jacobs M., Fan F., Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature. Ann Diagn Pathol 2012, 16(3):185-189.
150. Jung S.P., Lee S.K., Kim S., Choi M.Y., Bae S.Y., Kim J., et al. Invasive pleomorphic lobular carcinoma of the breast: clinicopathologic characteristics and prognosis compared with invasive ductal carcinoma. J. Breast Cancer 2012, 15(3):313-319.
151. Dubsky P.C., Jakesz R., Mlineritsch B., Postlberger S., Samonigg H., Kwasny W., et al. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2012, 30(7):722-728.
152. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11):1081-1092.
153. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Nat Cancer Inst 2005, 97(3):188-194.
154. Kaufmann M., von Minckwitz G., Bear H.D., Buzdar A., McGale P., Bonnefoi H., et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007, 18(12):1927-1934.
155. Dawood S., Merajver S.D., Viens P., Vermeulen P.B., Swain S.M., Buchholz T.A., et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011, 22(3):515-523.
156. von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30(15):1796-1804.
157. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer 2012, SABCS, San Antonio, TX. P.Z.L. Cortazar, M. Untch, K. Mehta, J. Costantino, N. Wolmark, H. Bonnefoi, D. Cameron, L. Gianni, P. Valagussa, J.A. Zujewski, R. Justice, S. Lobl, L. Wickerham, J. Bogaerts, J. Baselga, C. Perou, G. Blumenthal, J. Blohmer, E. Mamounas, J. Bergh, V. Semiglazov, T. Prowell, H. Eidtmann, S. Paik, M. Piccart, R. Sridhara, P. FAsching, S.M. Swain, L. Slaets, S. TAng, B. Gerber, C. Geyer, R. PAzdur, N. Ditsch, P. Rastogi, W. Eiermann, G. Von Minckwitz (Eds.).
158. Nagao T., Kinoshita T., Hojo T., Tsuda H., Tamura K., Fujiwara Y. The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: the relationship between the outcome and the clinicopathological characteristics. Breast 2012, 21(3):289-295.
159. Chaturvedi S., Chaturvedi H.S., Stevenson R.S.L. Primary chemotherapy for breast cancers: does histological type of cancer matter?. Bresat Cancer Res Treat 2004, 88(suppl 1):S106. (abstr 2089).
160. Lips E.H., Mukhtar R.A., Yau C., de Ronde J.J., Livasy C., Carey L.A., et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat 2012, 136(1):35-43.
161. Tubiana-Hulin M., Stevens D., Lasry S., Guinebretiere J.M., Bouita L., Cohen-Solal C., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006, 17(8):1228-1233.
162. Wenzel C., Bartsch R., Hussian D., Pluschnig U., Altorjai G., Zielinski C.C., et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel+G-CSF. Breast Cancer Res Treat 2007, 104(1):109-114.
163. Sullivan P.S., Apple S.K. Should histologic type be taken into account when considering neoadjuvant chemotherapy in breast carcinoma?. Breast J 2009, 15(2):146-154.
164. Colleoni M., Bagnardi V., Rotmensz N., Gelber R.D., Viale G., Pruneri G., et al. Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy. Breast Cancer Res Treat 2009, 116(2):359-369.
165. Katz A., Saad E.D., Porter P., Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol 2007, 8(1):55-62.
166. Joh J.E., Esposito N.N., Kiluk J.V., Laronga C., Khakpour N., Soliman H., et al. Pathologic tumor response of invasive lobular carcinoma to neo-adjuvant chemotherapy. Breast J 2012, 18(6):569-574.
167. Dieras V., Fumoleau P., Romieu G., Tubiana-Hulin M., Namer M., Mauriac L., et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004, 22(24):4958-4965.
168. Reitsamer R., Peintinger F., Prokop E., Hitzl W. Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs 2005, 16(8):867-870.
169. Untch M., Fasching P.A., Konecny G.E., von Koch F., Conrad U., Fett W., et al. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer-results at the time of surgery. Ann Oncol 2011, 22(9):1988-1998.
170. von Minckwitz G., Blohmer J.U., Raab G., Lohr A., Gerber B., Heinrich G., et al. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005, 16(1):56-63.
171. von Minckwitz G., Kummel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Nat Cancer Inst 2008, 100(8):542-551.
172. von Minckwitz G., Kummel S., Vogel P., Hanusch C., Eidtmann H., Hilfrich J., et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Nat Cancer Inst 2008, 100(8):552-562.
173. von Minckwitz G., Eidtmann H., Rezai M., Fasching P.A., Tesch H., Eggemann H., et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012, 366(4):299-309.
174. Chang H.R., Glaspy J., Allison M.A., Kass F.C., Elashoff R., Chung D.U., et al. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer 2010, 116(18):4227-4237.
175. Untch M., Loibl S., Bischoff J., Eidtmann H., Kaufmann M., Blohmer J.U., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 2012, 13(2):135-144.
176. Response pattern in 844 patients with infiltrating lobular carcinoma of the breast after neoadjuvant chemotherapy. ASCO annual meeting 2012, C.L.S. Pirvulescu, G. Von Minckwitz, C. Mau, J.U. Blohmer, S. Dan Costa, H. Eidtmann, P.A. Fasching, B. Gerber, M. Untch (Eds.).
177. Jirstrom K., Ryden L., Anagnostaki L., Nordenskjold B., Stal O., Thorstenson S., et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005, 58(11):1135-1142.
178. Metzger O.G.-H.A., Mallon E., Viale G., Winer E., Thürlimann B., Gelber R.D., Colleoni M., Ejlersten B., Bonenfoi H., Coates A.S., Goldhirsch A., Gusterson B. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial 2012, SABCS, San Antonio, TX. BIG 1-98 Collaborative Group, International Breast Cancer Study Group (Eds.).
179. Chow L.W., Yip A.Y., Loo W.T., Lam C.K., Toi M. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008, 111(1-2):13-17.
180. Dixon J.M., Renshaw L., Dixon J., Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat 2011, 130(3):871-877.
181. Barnadas A., Gil M., Gonzalez S., Tusquets I., Munoz M., Arcusa A., et al. Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial. Br J Cancer 2009, 100(3):442-449.
182. Xu B., Jiang Z., Shao Z., Wang J., Feng J., Song S., et al. Fulvestrant 250mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol 2011, 67(1):223-230.
183. Smith D.B., Howell A., Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987, 23(7):979-982.
184. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366(6):520-529.
185. Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 2012, 30(22):2718-2724.